4 Questions to Ask Your MD About Tirzepatide (Mounjaro) for Type 2 Diabetes

How to Decide if Tirzepatide (Mounjaro) Is the Right Type 2 Diabetes Drug for You

How to Decide if Tirzepatide (Mounjaro) Is the Right Type 2 Diabetes Drug for You
iStock

If you’re managing type 2 diabetes, you might wonder if the new headline-making injectable drugs with weight loss benefits are right for you.

One such drug is tirzepatide (prescribed as Mounjaro for type 2 diabetes and Zepbound for weight loss). This first-in-class GLP-1 and GIP receptor agonist was approved by the U.S. Food and Drug Administration (FDA) to lower blood sugar in adults and children age 10 and older with type 2 diabetes.

 In an expanded approval, the FDA also approved Mounjaro to reduce the risk of major cardiovascular events, such as heart attack and stroke, in adults with type 2 diabetes who have established heart disease or multiple cardiovascular risk factors.

Tirzepatide has been shown to be more effective at lowering hemoglobin A1C (HbA1c) and supporting weight loss in people with type 2 diabetes than semaglutide (Ozempic).

In direct head-to-head clinical trial comparisons, high-dose tirzepatide (15 milligrams) achieved greater reductions in HbA1c than both high- and low-dose semaglutide, and it delivered significantly greater weight loss. Real-world evidence similarly shows that adults with type 2 diabetes starting tirzepatide achieved greater 12-month reductions in blood sugar and body weight compared with those starting injectable semaglutide.

Specifically for patients who’d never taken a GLP-1 medication (GLP-1 naive), tirzepatide lowered HbA1c by an average of 1.3 percent, versus 0.9 percent for semaglutide, and it led to an average weight loss of 22.5 pounds, versus 13.4 pounds for semaglutide. For patients who had previously used a GLP-1 medication (nonnaive), tirzepatide reduced HbA1c by 0.9 percent, versus 0.6 percent for semaglutide, and resulted in 17.4 pounds of weight loss, with 8.2 pounds for semaglutide.

How Tirzepatide Works Differently Than Semaglutide

Tirzepatide mimics the actions of two distinct natural gut hormones that regulate blood sugar and appetite: glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). Since it targets both pathways at the same time, medical professionals classify tirzepatide as a dual GIP and GLP-1 receptor agonist.

Semaglutide (prescribed as Ozempic for type 2 diabetes and Wegovy for weight loss) is a single GLP-1 receptor agonist, meaning it targets only the GLP-1 pathway. While Mounjaro is strictly a once-weekly injection, semaglutide is available as either a weekly injection or a daily tablet. Other single GLP-1 receptor agonists include dulaglutide (Trulicity) and liraglutide (Victoza).

Both GLP-1 and GIP are incretin hormones released after eating. They signal to the pancreas to produce more insulin and prompt the brain to increase feelings of fullness. GLP-1 also slows gastric emptying (how quickly food leaves your stomach), which helps curb appetite and prevent postmeal blood sugar spikes.

According to Priya Jaisinghani, MD, an endocrinologist and clinical assistant professor at NYU Langone Medical Center, combining a GIP and GLP-1 receptor agonist into one medication helps make the medication tolerable even as doses increase. While adding a GIP agonist provides a dual approach to managing blood sugar and weight, patients on tirzepatide still frequently experience GLP-1 side effects, such as nausea, upset stomach, and vomiting.

“An important part of whether a patient takes their medication as prescribed is their ability to tolerate it and any side effects,” says Dr. Jaisinghani.

Infographic by Everyday Health titled "4 Questions to Ask About Tirzepatide (Mounjaro)" listing key topics to discuss with a doctor, including eligibility, diet and exercise, comparisons to current treatments, and cost.

4 Questions to Ask Your MD About Tirzepatide

Of course, your healthcare provider will want to understand all the nuances of how your body handles glucose before determining the best course of treatment for you, says Florence Comite, MD, an endocrinologist and the founder of the Center for Precision Medicine and Health in New York City.

Tests to determine your blood sugar levels, such as an oral glucose tolerance test, may be ordered to confirm a diagnosis of diabetes. Your fat and muscle composition may be assessed, as well. “Factoring in family health history, your own past medical history, habits, and lifestyle will help determine if Mounjaro is appropriate,” Dr. Comite says.

Here are questions to bring up with your doctor to help you and your care team decide if tirzepatide could help you manage blood sugar, support weight loss, and reduce your risk of cardiovascular events like heart attack and stroke.

1. Could Tirzepatide Work Better Than the Drugs I’m Currently Using?

If you have both type 2 diabetes and obesity or established cardiovascular disease, and there are no medical reasons to avoid tirzepatide, the medication could be an excellent choice, says Florencia Halperin, MD, a Boston-based endocrinologist and the chief medical officer of the weight loss clinic Form Health. “Mounjaro is very effective at both lowering blood sugar and causing weight loss,” she says.

In fact, according to the latest care standards released by the American Diabetes Association, tirzepatide is recognized as having “very high efficacy” for both blood sugar control and weight management.

You may also be a good tirzepatide candidate if you struggle to manage your blood sugar or reach your health goals despite taking a maximum dose of a traditional GLP-1 receptor agonist.

2. Does Tirzepatide Work Without Diet and Exercise?

It isn’t proven that you will get meaningful blood sugar and weight-lowering results by taking an injection alone. The FDA specifically approved Mounjaro as an adjunct to diet and exercise for managing type 2 diabetes.

“All of the studies that have been done showing safety and efficacy of Mounjaro have also included a lifestyle component, in which patients are counseled on healthy nutrition, physical activity, and behavior change,” says Dr. Halperin. “So discussing those aspects with the prescribing provider and making sure there is a good supportive plan for incorporating healthy habits are important as well.”

3. I’m Not Overweight or Obese — Could Tirzepatide Still Be Right for Me?

If you have type 2 diabetes, your doctor may prescribe tirzepatide to manage blood sugar, which can also reduce cardiovascular risk regardless of your weight.

If your body mass index (BMI) is in a lower range and you do not have type 2 diabetes, it is not for you, says Louis Aronne, MD, an endocrinologist and the director of the Center for Weight Management and Metabolic Clinical Research at Weill Cornell Medicine in New York City — at least, not yet. Future studies may reveal whether it’s safe and effective for those in lower BMI ranges, but for now, he adds, “I don't think that people in that lower weight range really need to be doing stuff like this.”

A doctor will evaluate several personal health factors before making the final decision. “I recommend that patients be prepared to disclose all of their medical and surgical history, medication and allergy history, and recent laboratory studies with any medical provider who might be considering it as a treatment,” Halperin says.

4. How Much Will Tirzepatide Treatment Cost?

There’s one more important variable that affects whether tirzepatide is right for someone. “Unfortunately, cost is often a very significant factor in the decision-making process,” says Halperin. “Patients who do not have insurance coverage for Mounjaro are likely to find it prohibitively expensive.”

According to Lilly, the list price for brand-name Mounjaro is $1,112.16 per one-month supply.

 Most health plans cover Mounjaro when prescribed for its FDA-approved uses in people with type 2 diabetes, such as lowering blood sugar and reducing cardiovascular risk, though out-of-pocket costs and copays vary depending on your specific plan.
While lower-cost GLP-1 and GIP options are frequently advertised online through telehealth platforms, these are typically compounded versions. The FDA cautions patients that unapproved compounded medications do not undergo the agency’s safety, quality, and effectiveness reviews.

EDITORIAL SOURCES
Everyday Health follows strict sourcing guidelines to ensure the accuracy of its content, outlined in our editorial policy. We use only trustworthy sources, including peer-reviewed studies, board-certified medical experts, patients with lived experience, and information from top institutions.
Resources
  1. Mounjaro (tirzepatide) Injection, for Subcutaneous Use. U.S. Food and Drug Administration. January 2026.
  2. US FDA approves Lilly's Mounjaro to Reduce Cardiovascular Risk. Reuters. August 28, 2026.
  3. Nye J. High-Dose Tirzepatide Linked to Greater HbA1c, Weight Loss vs Semaglutide. Endocrinology Advisor. April 23, 2026.
  4. Hoog M M et al. Real-World Effectiveness of Tirzepatide versus Semaglutide on HbA1c and Weight in Patients with Type 2 Diabetes. Diabetes Therapy. October 9, 2025.
  5. Tirzepatide vs Semaglutide: A Comprehensive Comparison for Providers. Obesity Medicine Association. August 14, 2026.
  6. Tirzepatide vs. Semaglutide. Cleveland Clinic. July 13, 2026.
  7. Standards of Care in Diabetes — 2026. American Diabetes Association. December 2025.
  8. Zepbound (tirzepatide) Injection, for Subcutaneous Use. U.S. Food and Drug Administration. March 2024.
  9. How Much Should I Expect to Pay for Mounjaro (Tirzepatide)? Lilly. January 1, 2026.
  10. FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss. U.S. Food and Drug Administration. September 1, 2026.
Elise-M-Brett-bio

Elise M. Brett, MD

Medical Reviewer
Elise M Brett, MD, is a board-certified adult endocrinologist. She received a bachelor's degree from the University of Michigan and her MD degree from the Icahn School of Medicine ...

Sheryl Huggins Salomon

Author

Sheryl Huggins Salomon has spent her career equipping people with information to help improve their well-being and prospects in life. She is a veteran journalist and editor who has...